

## Emtricitabine (Emtriva, FTC)

(Last updated December 29, 2020; last reviewed December 29, 2020)

### Animal Studies

#### *Carcinogenicity*

Emtricitabine (FTC) was neither mutagenic nor clastogenic in a series of *in vitro* and animal *in vivo* screening tests. In long-term carcinogenicity studies of oral FTC, no drug-related increases in tumor incidence were found at doses up to 26 times (in mice) or 31 times (in rats) the exposures seen in humans who received the therapeutic dose.<sup>1</sup>

#### *Reproduction/Fertility*

FTC had no observable effect on reproduction or fertility at doses that produced systemic drug exposures (as measured by area under the curve [AUC]) that were approximately 60-fold higher in female and male mice and 140-fold higher in male rats than human exposure at the recommended therapeutic dose.<sup>1</sup>

#### *Teratogenicity/Adverse Pregnancy Outcomes*

No fetal variations or malformations were observed following maternal FTC doses that produced systemic drug exposures that were 60-fold higher (in mice) or 120-fold higher (in rabbits) than those observed in humans who received the recommended dose.<sup>1</sup>

#### *Placental and Breast Milk Passage*

FTC has been shown to cross the placenta in mice and rabbits; the average fetal/maternal drug concentration ratio was 0.4 in mice and 0.5 in rabbits.<sup>2</sup>

### Human Studies in Pregnancy

#### *Pharmacokinetics*

In the IMPAACT P1026s study, FTC exposure was modestly lower during the third trimester (geometric mean 8.0 mcg•h/mL; 90% confidence interval [CI], 7.1–8.9 mcg•h/mL) than during the postpartum period (9.7 mcg•h/mL; 90% CI, 8.6–10.9 mcg•h/mL). Fifty-eight percent of pregnant women (15 of 26 women) met the AUC target ( $\leq 30\%$  reduction from typical exposure for nonpregnant historical controls) compared to 95% of postpartum women (21 of 22 women). Trough FTC levels also were lower during pregnancy ( $C_{24h}$  geometric mean concentration [GMC] 58 ng/mL; 90% CI, 37–63 ng/mL) than during the postpartum period ( $C_{24h}$  GMC 85 ng/mL; 90% CI, 70–100 ng/mL).<sup>3</sup> Similar differences in pharmacokinetic parameters of FTC were found among women during pregnancy or after delivery in the PACTG 394 study<sup>4</sup> and in a European study.<sup>5,6</sup> The increase in FTC clearance during pregnancy correlated with the normal pregnancy-related increase in glomerular filtration rate.<sup>6</sup> These changes are not believed to be large enough to warrant a dose adjustment during pregnancy.

#### *Placental and Breast Milk Passage*

FTC has been shown to have high placental transfer in pregnant women. In a study of 15 women who received FTC during pregnancy, the mean cord blood-to-maternal-plasma ratio was 1.2 (90% CI, 1.0–1.5).<sup>3</sup> In eight women who were given a single dose of FTC 600 mg with tenofovir disoproxil fumarate (TDF) 900 mg, the median cord blood FTC concentration was 717 ng/mL (range, 21–1,072 ng/mL), and the median cord blood-to-maternal-plasma ratio was 0.85 (range, 0.46–1.07).<sup>4</sup>

FTC is excreted into human milk. Among women in Uganda and Nigeria who were taking first-line antiretroviral therapy that contained FTC 200 mg, FTC concentrations in breast milk peaked later than they did in maternal plasma (at 4–8 hours compared with 2–4 hours) and were threefold higher than maternal plasma concentrations. FTC was detectable in three infants (19%).<sup>7</sup> In a study in the Ivory Coast, five women with HIV who exclusively breastfed their newborn infants were given FTC 400 mg, TDF 600 mg, and nevirapine

200 mg at onset of labor, followed by FTC 200 mg and TDF 300 mg once daily for 7 days postpartum. The median minimal and maximal concentrations of FTC in breast milk were 177 ng/mL and 679 ng/mL, respectively (interquartile ranges [IQR], 105–254 ng/mL and 658–743 ng/mL, respectively), well above the estimated FTC 50% inhibitory concentration (IC<sub>50</sub>) for HIV-1.<sup>8</sup> In a study of 50 women without HIV who received daily oral FTC 200 mg and TDF 300 mg as pre-exposure prophylaxis (PrEP), median peak and trough breast milk concentrations of FTC were 212.5 ng/mL (IQR 140.0–405.0 ng/mL) and 183.0 ng/mL (IQR 113.0–250.0 ng/mL), respectively. FTC was detectable in 47 of 49 infants at a median concentration of 13.2 ng/mL (IQR 9.3–16.7 ng/mL), corresponding to estimated daily infant ingestion of a 31.9-mcg/kg dose (IQR 21.0–60.8 mcg/kg) of FTC, or 0.5% of the daily dose for treating infants.<sup>9</sup>

### ***Teratogenicity/Adverse Pregnancy Outcomes***

A study of pregnancies conducted during an HIV PrEP trial randomized participants without HIV to receive placebo, TDF, or TDF plus FTC. No increase in the incidence of congenital anomalies was observed in the TDF plus FTC arm.<sup>10</sup> There was no overall difference between the rate of pregnancy loss in the TDF plus FTC arm and the rate of pregnancy loss in the TDF arm of this PrEP study.

In the U.S. PHACS/SMARTT cohort study, FTC exposure was not associated with an increase in specific or overall birth defect risk.<sup>11</sup> In a large French cohort, FTC exposure in the first trimester was associated with lower risk of birth defects.<sup>12</sup> The Antiretroviral Pregnancy Registry has monitored sufficient numbers of first-trimester exposures to FTC to detect at least a 1.5-fold increased risk of overall birth defects and at least a twofold increase in cardiovascular and genitourinary defects (**the most common classes of birth defects in the general population**). No such increase in the risk of birth defects has been observed with FTC. Among the cases of first-trimester FTC exposure that have been reported to the Antiretroviral Pregnancy Registry, the prevalence of birth defects was **2.6%** (94 of **3,601** live births; 95% CI, **2.1%** to **3.2%**) compared with a total prevalence of **2.7%** in the U.S. population, based on Centers for Disease Control and Prevention surveillance.<sup>13</sup>

### ***Other Safety Information***

In the U.S. PHACS/SMARTT cohort study, after adjusting for birth cohort and other factors, maternal use of FTC led to no increase in the likelihood of adverse metabolic, growth and development, cardiac, neurological, or neurodevelopmental outcomes.<sup>14</sup>

## Excerpt from Table 10

**Note:** When using FDC tablets, refer to other sections in Appendix B and Table 10 for information about the dosing and safety of individual drug components of the FDC tablet during pregnancy.

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations <sup>a</sup>	Use in Pregnancy
<p><b>Emtricitabine</b> (FTC) <i>Emtriva</i></p> <p>(FTC/EFV/TDF) <i>Atripla</i></p> <p>(FTC/BIC/TAF) <i>Biktarvy</i></p> <p>(FTC/RPV/TDF) <i>Complera</i></p> <p>(FTC/TAF) <i>Descovy</i></p> <p>(FTC/EVG/c/TAF) <i>Genvoya</i></p> <p>(FTC/RPV/TAF) <i>Odefsey</i></p> <p>(FTC/EVG/c/TDF) <i>Stribild</i></p> <p>(FTC/DRV/c/TAF) <i>Symtuza</i></p> <p>(FTC/TDF) <i>Truvada</i></p> <p><b>Note:</b> Generic products are available for some formulations.</p>	<p><b>FTC (Emtriva)</b> <i>Capsule:</i><sup>d</sup></p> <ul style="list-style-type: none"> <li>• 200 mg</li> </ul> <p><i>Oral Solution:</i></p> <ul style="list-style-type: none"> <li>• 10 mg/mL</li> </ul> <p><b>FTC/EFV/TDF (Atripla):</b><sup>d</sup></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/EFV 600 mg/TDF 300-mg tablet</li> </ul> <p><b>FTC/BIC/TAF (Biktarvy):</b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/BIC 50 mg/TAF 25-mg tablet</li> </ul> <p><b>FTC/RPV/TDF (Complera):</b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/RPV 25 mg/TDF 300-mg tablet</li> </ul> <p><b>FTC/TAF (Descovy):</b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/TAF 25 mg tablet</li> </ul> <p><b>FTC/EVG/c/TAF (Genvoya):</b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/EVG 150 mg/COBI 150 mg/TAF 10-mg tablet</li> </ul> <p><b>FTC/RPV/TAF (Odefsey):</b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/RPV 25 mg/TAF 25 mg tablet</li> </ul>	<p><b>Standard Adult Doses</b> <i>FTC (Emtriva)</i> <u>Capsule:</u></p> <ul style="list-style-type: none"> <li>• FTC 200 mg once daily without regard to food</li> </ul> <p><u>Oral Solution:</u></p> <ul style="list-style-type: none"> <li>• FTC 240 mg (24 mL) once daily without regard to food</li> </ul> <p><i>FTC/EFV/TDF (Atripla):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily at or before bedtime</li> <li>• Take on an empty stomach to reduce or mitigate side effects.</li> </ul> <p><i>FTC/BIC/TAF (Biktarvy):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily with or without food</li> </ul> <p><i>FTC/RPV/TDF (Complera):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily with food</li> </ul> <p><i>FTC/TAF (Descovy):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily with or without food</li> </ul> <p><i>FTC/EVG/c/TAF (Genvoya):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily with food</li> </ul> <p><i>FTC/RPV/TAF (Odefsey):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily with food</li> </ul> <p><i>FTC/EVG/c/TDF (Stribild):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily with food</li> </ul>	<p>High placental transfer to fetus.<sup>b</sup></p> <p>No evidence of human teratogenicity (can rule out 1.5-fold increase in overall birth defects).</p> <p>If patient has HBV/HIV coinfection, it is possible that a HBV flare may occur if the drug is stopped; see <a href="#">Hepatitis B Virus/HIV Coinfection</a>.</p>

Generic Name (Abbreviation) <i>Trade Name</i>	Formulation	Dosing Recommendations <sup>a</sup>	Use in Pregnancy
	<p><b>FTC/EVG/c/TDF (Stribild):</b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/EVG 150 mg/COBI 150 mg/TDF 300-mg tablet</li> </ul> <p><b>FTC/DRV/c/TAF (Symtuza):</b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/DRV 800 mg/COBI 150 mg/TAF 10-mg tablet</li> </ul> <p><b>FTC/TDF (Truvada):<sup>d</sup></b></p> <ul style="list-style-type: none"> <li>• FTC 200 mg/TDF 300-mg tablet</li> </ul>	<p><i>FTC/DRV/c/TAF (Symtuza):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily with food</li> </ul> <p><i>FTC/TDF (Truvada):</i></p> <ul style="list-style-type: none"> <li>• One tablet once daily without regard to food</li> </ul> <p><b>Pregnancy</b></p> <p><i>PKs in Pregnancy:</i></p> <ul style="list-style-type: none"> <li>• PKs of FTC are not significantly altered in pregnancy.</li> </ul> <p><i>Dosing in Pregnancy:</i></p> <ul style="list-style-type: none"> <li>• No change in dose indicated.</li> </ul> <p>For guidance about the use of combination products in pregnancy, please see the specific sections on other components (i.e., <a href="#">TDF</a>, <a href="#">TAF</a>, <a href="#">EFV</a>, <a href="#">RPV</a>, <a href="#">DRV</a>, <a href="#">EVG</a>, <a href="#">BIC</a>, <a href="#">COBI</a>).</p>	

<sup>a</sup> Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the [Adult and Adolescent Antiretroviral Guidelines, Appendix B, Table 10](#)).

<sup>b</sup> Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:

**High:** >0.6

**Moderate:** 0.3–0.6

**Low:** <0.3

<sup>d</sup> Generic product available

**Key:** BIC = bictegravir; COBI = cobicistat; DRV/c = darunavir/cobicistat; EFV = efavirenz; EVG/c = elvitegravir/cobicistat; FDC = fixed-dose combination; FTC = emtricitabine; HBV = hepatitis B virus; PK = pharmacokinetic; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate

## References

1. Emtricitabine (Emtriva) [package insert]. Food and Drug Administration. 2018. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/021896s026lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021896s026lbl.pdf).
2. Szczech GM, Wang LH, Walsh JP and Rousseau FS. Reproductive toxicology profile of emtricitabine in mice and rabbits. *Reprod Toxicol*. 2003;17(1):95–108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12507664>.
3. Stek AM, Best BM, Luo W, et al. Effect of pregnancy on emtricitabine pharmacokinetics. *HIV Med*. 2012;13(4):226–235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22129166>.
4. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. *Antimicrob Agents Chemother*. 2011;55(12):5914–5922. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21896911>.
5. Colbers AP, Hawkins DA, Gingelmaier A, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. *AIDS*. 2013;27(5):739–748. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23169329>.
6. Valade E, Treluyer JM, Dabis F, et al. Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics. *Br J Clin Pharmacol*. 2014;78(6):1378–1386. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24995851>.
7. Waitt C, Olagunju A, Nakalema S, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. *J Antimicrob Chemother*. 2018;73(4):1013–1019. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29309634>.
8. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 tEmAA study, step 2. *Antimicrob Agents Chemother*. 2011;55(3):1315–1317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21173182>.
9. Mugwanya KK, Hendrix CW, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. *PLoS Med*. 2016;13(9):e1002132. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27676257>.
10. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. *JAMA*. 2014;312(4):362–371. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25038355>.
11. Williams PL, Crain M, Yildirim C, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. *JAMA Pediatr*. 2015;169(1):45–55. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25383770>.
12. Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). *PLoS Med*. 2014;11(4):e1001635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24781315>.
13. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 January 1989–31 January 2020. Wilmington, NC: Registry Coordinating Center. 2020. Available at: <http://www.apregistry.com>.
14. Williams PL, Hazra R, Van Dyke RB, et al. Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design. *AIDS*. 2016;30(1):133–144. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26731758>.